Avicanna Academy

Cannabinoids in Pain Management

Dr. Hance Clarke, MD, PhD, University Health Network

Hance Clarke is a staff anesthesiologist and the Director of Pain Services and the Pain Research Unit at the Toronto General Hospital. Dr. Clarke is currently the knowledge Translation Chair For the University of Toronto Centre For the Study of Pain and in 2016, Dr. Clarke was awarded an early Career Award from the Canadian Pain Society. He has been recognized internationally for his research productivity and improvements to patient care such as the development of the Transitional Pain Program. Dr. Clarke has also played a leading role in educating the Canadian public about pain control, risk factors for chronic opioid use, alternatives to opioids as a pioneering strategy at TGH, misconceptions about opioid use, and the need for further studies on understanding the beneficial and adverse effects of cannabis. He is a strong public champion of evidence-based solutions for the opioid crisis and a national pain and addictions strategy.

Abstract:Neuropathic pain is a major source of morbidity with an estimated 45 million people globally suffering from this condition. There are many causes of neuropathic pain and this condition has been treated with conventional analgesics and anti-inflammatory agents. First line therapeutic agents include anti-depressants and anti-convulsants and selective serotonin and norepinephrine reuptake inhibitors (SNRIs)* . Yet many patients do not obtain relief from their pain. Opioids often become the mainstay of treating intractable neuropathic pain which can become problematic long-term. An overview of the use of cannabis in pain medicine and the its potential uses longterm will be discussed in this presentation.

*Moulin D, Boulanger A, Clark AJ, Clarke H, Dao T, Finley GA, Furlan A, Gilron I, Gordon A, Morley-
Forster PK, Sessle BJ, Squire P, Stinson J, Taenzer P, Velly A, Ware MA, Weinberg EL, Williamson OD;
Canadian Pain Society. Pharmacological management of chronic neuropathic pain: revised consensus
statement from the Canadian Pain Society. Pain Res Manag. 2014 Nov-Dec;19(6):328-35.

Dr. Robert Bonin, MD, PhD, University of Toronto

Rob Bonin is an Assistant Professor in the Leslie Dan Faculty of Pharmacy at the University of Toronto. He holds the Canada Research Chair in Sensory Plasticity and Reconsolidation and is a Scientist with the University of Toronto Centre for the Study of Pain. Dr. Bonin is exploring the synaptic changes in the spinal cord that contribute to abnormal sensory processing and is developing new models to study natural pain behaviour in animals.

Dr. Mohit Kapoor, PhD, University of Toronto

Dr. Mohit Kapoor is the Director of Arthritis Research Program (the largest multidisciplinary Arthritis Research Program in Canada) at the University Health Network (Toronto), where he is directing basic, clinical, and translational research in arthritis. He is the Tier 1 Canada Research Chair in the Mechanisms of Joint Degeneration. Dr. Kapoor’s translational research program is directed towards: (1) Understanding the complex cellular and molecular mechanisms associated with joint destruction during osteoarthritis; (2) Identifying reliable biomarkers for early identification of patients with osteoarthritis to enable early intervention; (3) Identifying novel therapeutic targets to stop/delay osteoarthritis and restore joint function.

His research is funded by various research organizations including the Canadian Institute of Health Research (CIHR), Canada Research Chair Program, Canadian Foundation for Innovation (CFI), Natural Sciences and Engineering Research Council of Canada (NSERC), Krembil Foundation, The Arthritis Society, Stem Cell Network, etc. He also sits on review panels & boards of various research/funding organizations across the globe. He has published over 80 research articles, reviews, and book/book chapters. His research work has been published in journals including Nature Medicine, Science Translational Medicine, Annals of The Rheumatic Diseases, Nature Reviews Rheumatology, etc.

Dr. Sefi Kronenberg, The Hospital for Sick Children

Dr. Sefi Kronenberg is a psychiatrist within the Department of Psychiatry at The Hospital for Sick Children (SickKids) and an Assistant Professor of Psychiatry at the University of Toronto. Dr. Kronenberg completed his academic training at Tel-Aviv University (Israel) receiving both an MD and a PhD in pharmacogenetics. After which, he completed a five-year residency in child and adolescent psychiatry at Schneider Children's Medical Center of Israel and Ge’ha Mental Health Center. Upon graduation, he worked as the head of the paediatric ER at Ge’ha Mental Health Center. Kronenberg joined SickKids in 2013. He came onboard as a fellow focusing on the clinical and biological aspects of obsessive-compulsive disorder (OCD).

Since 2016 he has been working principally with SickKids’ pain services including: acute, transitional, and chronic pain services. Kronenberg is also a member of the chronic pain intensive rehabilitation program at Holland-Bloorview Kids Rehabilitation Hospital (Get Up and Go Program). In 2017, Dr. Kronenberg became the mental health lead of the chronic pain service.

Dr. Karim Ladha, St. Michael’s Hospital

Dr. Karim Ladha is a clinician-scientist and staff anesthesiologist at St. Michael’s Hospital and the University of Toronto. Dr. Ladha received his medical degree from the Johns Hopkins University School of Medicine. He then completed his anesthesia training at the Massachusetts General Hospital and obtained a fellowship in cardiac anesthesia in Toronto. He also holds a Master’s degree in clinical epidemiology from the Harvard School of Public Health. His program of research uses mixed methodologies to obtain a multifaceted view of acute and chronic pain including retrospective analyses of administrative databases, prospective observational studies, and multi-center randomized controlled trials. His research has been published in top-tier journals including JAMA, BMJ, British Journal of Anesthesia and Anesthesiology. This past year, he received the prestigious International Anesthesia Research Society Mentored Research Award for his potential to influence the field of Anesthesia.

Section 3: Therapeutic Area Focus

Moderator: Dr. Rahul Sarugaser, Paradigm Capital Inc.

Rahul is an equities research analyst covering the biotechnology, healthcare, and cannabis sectors at Paradigm Capital. Rahul holds a PhD and MASc in biomedical engineering from the University of Toronto, and an MBA from the University of Oxford. Prior to Paradigm, his roles included Director of Business Development at the Centre for Commercialization of Regenerative Medicine, Investment Manager with the Toronto-based MaRS Investment Accelerator Fund, and Strategic Marketing Analyst with GE Healthcare’s headquarters in the U.K.

Canada’s Leadership Position in the Emerging Global Industry

Aras Azadian, Avicanna Inc.

Aras brings extensive senior management experience in the biotechnology and financial sectors including his involvement in several successful start-up companies. In addition to his international experience in corporate development, his diverse roles include his previous position as the president of an investment corporation in the cannabis space and former Chief Operating Officer of an oncology company. Aras holds a Bachelor of Economics degree from York University in Toronto, and an International Masters in Management degree from EADA Business School in Barcelona, Spain.

Abstract: As the first G8 country to federally legalize medicinal and now recreational cannabis, Canada has established itself as a forerunner in this sector and has therefore secured an early leadership position in the blossoming industry at a global level. This position can be attributed to early access to financing and capital markets, which has been fruitful for the early Canadian licensed producers as well as the investment community.

As the industry continues to evolve, Canadian firms hoping to sustain this leadership position need to acknowledge that with this opportunity comes a responsibility, specifically to scientific vigor, environmental sustainability and strict quality controls.

We are at a crossroads, where we have the potential to establish a legitimate and sustainable industry within Canada or we risk losing our position as global pioneers.

Javier Hasse, Benzinga

Javier Hasse is a Latinx cannabis-focused writer and author of the best-selling book, "Start Your Own Cannabis Business," published via Entrepreneur Media. In addition, Javier is an award-winning reporter with more than 4,700 unique articles published across numerous mass media outlets including CNBC, Playboy, Forbes, Entrepreneur Mag, TheStreet.com, High Times, Leafly, Dope Magazine, Benzinga, CNN Money, Yahoo Finance, MarketWatch, MSN Money, Morningstar, and many others.

In addition, Javier serves as the Managing Director of Benzinga's Cannabis division, hosts and produces multimedia shows, sits on advisory boards at cannabis companies in emerging markets, has recorded songs that were featured on Billboard charting albums with big names like Wu Tang Clan's RZA and Twista, and publishes his photography very often.

Michael Astone, CPA, CA, BMO Capital Markets

Michael Astone is currently the Vice President of Cannabis Investment Banking at BMO Capital Markets. Prior to this role, Michael was an Investment Bank Associate with TD Securities for five years. Michael graduated in the top 30% on the SOA exam and earned his CPA in 2011, and holds a BBA degree in Accounting and Finances from the University of Guelph.

Stephen Murphy, Prohibition Partners

Stephen Murphy is a cannabis specialist focused on developing the legal European and international cannabis industry. With a background in technology, digital media and corporate finance, he is focused on delivering innovation, insights and growth to all aspects of work. He is the Co-Founder of Prohibition Partners, the leading source of intelligence and insight into the international cannabis industry. His team works with investors, entrepreneurs and regulators to identify, qualify and maximise the opportunities in this emerging frontier.

Stephen is also a Co-Founder & Director of European Cannabis Holdings and Co-Founder of Cannabis Europa.

Dr. Kaivan Talachian, PhD, CannTrust Inc.

Kaivan Talachian holds a doctorate in pharmacy (Pharm.D., R.Ph.) and is a practicing pharmacist in Canada with more than 20 years of diverse experience in pharmaceutical, medical device and healthcare information technology. He has conducted numerous educational sessions on medical cannabis across the country. Kaivan is the vice president of professional services at CannTrust, in this capacity he is responsible for medical business and advocacy relationships.

Closing Remarks

Aras Azadian, Avicanna Inc.

Aras brings extensive senior management experience in the biotechnology and financial sectors including his involvement in several successful start-up companies. In addition to his international experience in corporate development, his diverse roles include his previous position as the president of an investment corporation in the cannabis space and former Chief Operating Officer of an oncology company. Aras holds a Bachelor of Economics degree from York University in Toronto, and an International Masters in Management degree from EADA Business School in Barcelona, Spain.

Thank you for joining us for Avicanna Inc.’s first Canadian educational symposium.

We hope you found the day informative, thought-provoking and a means to spark ongoing meaningful and transparent discussion, discovery and collaboration when it comes to the research and the evolving role of cannabinoids in a medical setting. It is an exciting time in our industry and our goal is to continue to provide you and your colleagues with information, education, as well as responsible, innovative, and evidence-based health solutions.

We extend our appreciation to our moderators, experts and panelists both here at home and those who travelled to share their expertise.

We look forward to your feedback on the day and your continued insights, questions and recommendations for further events.

Cannabinoids in Oncology

Dr. Alejandro Berlin, MD, MSC, Princess Margaret Cancer Centre

Dr. Berlin trained in Chile, Israel and Canada, and currently works as a staff Clinician-Scientist Radiation Oncologist at the Princess Margaret Cancer Centre. His practice focuses in the characterization of malignancies with MRI and molecular imaging, and original applications of combinatorial approaches using systemic agents, stereotactic and MRI-guided ablative treatments. He is particularly interested in the design of innovative clinical trials, translational oncology, and genomic-based biomarker discovery, conveying his clinical and research expertise towards novel treatments for patients with cancer.

Abstract: The active components of Cannabis sativa and their derivatives (i.e. Cannabinoids) have increasingly recognized favorable effects for managing cancer- and treatment-related symptoms such as nausea, vomiting, pain, anorexia. In addition, these compounds have been shown to delay and/or inhibit the growth of tumor cells in pre-clinical studies. In the context of a rapidly changing scientific, clinical and legal landscape for exploiting Cannabinoids attributes, we discuss their role in oncology. Particularly, the pressing need for clinical research and drug development strategies that could expand the therapeutic armamentarium and ultimately improve outcomes for cancer patients.

Dr. Claudia Buitrago, PhD, Colombian Association of Palliative Care

Dr. Claudia Buitrago is currently the President of the Colombian Association of Palliative Care and Head of the Pain Medicine and Palliative Care Service at Hospital of San José. Bogotá, Colombia. She also has a fellowship head Pain medicine and Palliative care at University Foundation of Health Sciences FUCS. Clinical Epidemiologist, Hospital de San José.

Dr. Justin Grant, PhD, MBA, Princess Margaret Cancer Centre

Dr. Justin Grant has over fifteen years experience in leading pharmaceutical research in sustained drug release formulations. He held academic appointments at the University of Toronto’s Faculty of Pharmacy and UHN’s Techna Institute for the Advancement of Technology for Health. For over 10 years, he has managed a $50M preclinical cancer research facility (the STTARR Innovation centre) at Princess Margaret Cancer Centre. Justin is currently the Chair of the Scientific Advisory Board for Avicanna.

Dr. Zohar Koren, PhD MBA, SciCann Therapeutics Inc.

Dr. Koren is the co-founder and CEO of SciCann Therapeutics Inc., a Canadian-Israeli speciality pharmaceutical firm dedicated to the development of cutting-edge technologies in the pharmaceutical cannabinoid space. He is the VP BD of Mor Research Applications, commercial unit of Clalit Healthcare Services, World’s second largest HMO, with 14 hospitals and $6B annual turnover. Dr. Koren is also the VP BD of Talent Biotechs, a developer of CBD based drugs for the treatment and prevention of GVHD (Graft Vs Host Disease). Dr. Koren is also the co-founder and CEO of Cannabics Pharmaceuticals Inc. (OTCQB:CNBX), a developer of cannabis based therapies for oncology patients. He is the director of Business Development at Aposense Ltd (TASE:APOS), a developer of novel pharmaceutical products in the oncology, CNS and metabolic disease fields. Dr. Koren holds a Ph.D. and M.Sc. in Protein science and computational biology from the University of Haifa, and a B.Sc. in Mathematics, Physics and Biology from the Hebrew University in Jerusalem. Dr. Koren is a veteran of the prestigious “Talpiyot” program of the Israeli Defence Forces, an elite unit designed to qualify the top technology officers of the IDF.

Cannabinoids in Epilepsy

Dr. Amza Ali, MBBS, DM, MSc, FRCP, FACP, FAAN, FAES, MBA, University of the West Indies/Avicanna Inc.

Dr. Amza Ali MD, FRCP, trained in neurology and clinical neurophysiology in both the United Kingdom and in the United States. He has received international recognition for his work in the Caribbean related to advancing the care of patients with epilepsy and was recently chosen as an Ambassador for Epilepsy by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). The development of a sustainability model in his current doctoral program, at the Henley Business School in the United Kingdom, drives his interest in new pharmacological solutions for epilepsy and other neurological conditions. Dr. Ali holds a Masters in Business Administration from the Rotman School of Management, University of Toronto. He is a Fellow of the American Epilepsy Society and the President of the Epilepsy Society of the Caribbean.Epilepsy Society.

Abstract: For centuries and by many cultures, cannabis has been used for the treatment of neurological symptoms. Legal restrictions since 1937 slowed the exploration of its true value as a medicinal agent but, driven by numerous clinical anecdotes and early studies of varying rigour as well as high patient acceptability as a natural agent, changing regulatory landscapes are permitting its rigorous evaluation in the treatment of several chronic neurological ailments including pain syndromes, multiple sclerosis, neurodegenerative conditions and epilepsy. The panel will explore this area of research, focusing in particular on the field of epilepsy.

Dr. Peter Carlen, University of Toronto

Peter L. Carlen, MD, FRCP(C), was trained in Medicine and Neurology at the University of Toronto. He studied cellular electrophysiology for three years at the Neurobiology Department of the Hebrew University of Jerusalem. He then returned to Toronto where he was a staff neurologist and researcher at the Toronto Western Hospital and the Addiction Research Foundation starting in 1975. In 1989, he was appointed Director of the Playfair Neuroscience Unit and Neuroscience Research at the University Health Network for a 10 year term, where he is now a senior scientist and neurological clinician. He is also a professor in the Departments of Medicine (Neurology) and Physiology of the University of Toronto. His main research interests are mechanisms of neural synchrony and entrainment (epilepsy, movement disorders), neuroprotection and CNS aging.

Abstract: For centuries and by many cultures, cannabis has been used for the treatment of neurological symptoms. Legal restrictions since 1937 slowed the exploration of its true value as a medicinal agent but, driven by numerous clinical anecdotes and early studies of varying rigour as well as high patient acceptability as a natural agent, changing regulatory landscapes are permitting its rigorous evaluation in the treatment of several chronic neurological ailments including pain syndromes, multiple sclerosis, neurodegenerative conditions and epilepsy. The panel will explore this area of research, focusing in particular on the field of epilepsy.

Dr. Kevin Chapman, MD, Children's Hospital Colorado

Dr. Chapman is currently the Associate Professor of Pediatrics-Neurology at the Children’s Hospital Colorado. His clinical focus is caring for patients with complex epilepsy utilizing medical management, Vagus Nerve Stimulation (VNS) therapy, ketogenic diet, and epilepsy surgery. Dr. Chapman obtained his doctorate at the University of Texas Medical Branch School of Medicine, and has a special interest in electrical status epileptics during sleep (ESES).

Dr. Lawrence Hirsch, MD, Yale University

Dr. Hirsch completed medical school and internship at Yale University, neurology residency at Columbia University in New York City, and a two-year fellowship in Epilepsy and EEG at Columbia. He remained at Columbia on the faculty from 1997-2011. He moved to Yale University in 2011 as Professor of Neurology, Chief of Epilepsy and EEG, and Co-Director of the Yale Comprehensive Epilepsy Center. He has had leadership roles in multiple societies, including the American Clinical Neurophysiology Society, the American Epilepsy Society and the American Academy of Neurology.

Dr. Hirsch has published more than 200 peer-reviewed manuscripts and more than 100 invited reviews, editorials or chapters. His research interests and publications are on topics such as brain monitoring with EEG in the critically ill, status epilepticus, brain stimulation for epilepsy, epilepsy surgery, seizure semiology, electrocorticography, brain mapping, effectiveness and tolerability of antiepileptic drugs, seizure clusters, and sudden unexpected death in epilepsy (SUDEP). Dr. Hirsch has directed symposia and lectured at many national and international epilepsy and neurology meetings, and has won multiple teaching awards.

Dr. Blathnaid McCoy, MD, The Hospital for Sick Children

Dr. Blathnaid McCoy graduated from UCD medical school, and trained in paediatrics and paediatric neurology in Ireland. She completed an epilepsy fellowship at the Hospital for Sick Children and is a certified electroencephalographer (CSCN). She has an M.Sc in clinical epidemiology from the University of Toronto. She worked as a staff paediatric neurologist in Dublin, and currently works as a clinician investigator in the Division of Neurology at the Hospital for Sick Children, and an Assistant Professor of Paediatrics at the University of Toronto.
Her clinical focus is the management of refractory epilepsy; she is part of the comprehensive epilepsy surgery evaluation team, a Co-Director of the Infantile Spasms Clinic & Director of the Tuberous Sclerosis Complex Multidisciplinary Clinic.

Cannabinoids in Dermatology

Dr. Elena Pope, MD, The Hospital for Sick Children

Dr. Elena Pope is a Professor in the Department of Paediatrics at the University of Toronto. In 2003, she became the Director of the Section of Dermatology, Division of Paediatric Medicine at the Hospital for Sick Children, Toronto, Ontario, Canada. She received her medical training at The Institute of Medicine and Pharmacy, Bucharest Romania and the University of Toronto, and completed her training in Paediatrics and a fellowship in Pediatric Dermatology at the Hospital for Sick Children, Toronto. Since becoming Director of Paediatric Dermatology, Dr. Pope has instituted innovative approaches to the care of paediatric dermatological conditions by establishing interdisciplinary clinics in Epidermolysis Bullosa, Cutaneous T-cell lymphoma, Vascular Tumor Clinic, Morphea and Genodermatoses. She is a Project Investigator at the Research Institute, Hospital for Sick Children and is involved in numerous research projects stemming from her clinical interests focused on new interventions for rare and common pediatric dermatology conditions. Dr. Pope has many teaching commitments at the Hospital for Sick Children and has been the recipient of the Department of Paediatrics' Postgraduate Subspecialty Teaching Award. Dr. Pope has held leadership positions in PeDRA (Pediatric Dermatology Research Alliance)- past chair of the grants committee, current chair of the communication committee and member of the PeDRA’s Executive Committee and Board of Directors.

Abstract: Cannabinoids have been used as natural medicines for centuries; however, their biological activity in the skin is a new area of study. Recent data suggests that cannabinoids are involved in neuro-immuno-endocrine modulation of skin functioning. Specifically, cannabinoids have an inhibitory effect on skin inflammation, proliferation, fibrosis, pain, and itch, biological mechanisms involved in the pathogenesis of many dermatologic conditions. These mechanisms make cannabinoids attractive for conditions such as dermatitis, acne, localized scleroderma and due to their wound healing properties for management of orphan conditions such as epidermolysis bullosa.

Dr. Irene Lara-Corrales, The Hospital for Sick Children

Dr. Irene Lara-Corrales is an Associate Professor of Pediatrics at the University of Toronto and a staff physician in Pediatric Dermatology at the Hospital for Sick Children in Toronto, Canada. She completed her medical training and pediatric residency at the University of Costa Rica, in San Jose, Costa Rica and her pediatric dermatology training at the Hospital for Sick Children. She obtained a Master in Science degree from the University of Toronto. She is involved in numerous clinical and research endeavours, as well as in teaching commitments. She co-directs the Genodermatoses, Epidermolysis Bullosa, Vascular Tumors and Café-au-Lait. Screening clinics at SickKids. She is also the co-chair of the hospital’s Wound Care Committee. Her research interests include genodermatoses, inflammatory diseases and vascular anomalies.

Dr. Mauricio Torres-Pradilla, MD, PhD, Fundación Universitaria de Ciencias de la Salud

Dr. Mauricio Torres Pradilla is a Dermatologist with a specialization in pediatric dermatology. He has been involved in research on Atopic Dermatitis, Psoriasis, Epidermolysis Bullosa and Hemangiomas in Europe and South America. Mauricio has several publications on these topics, individually and in collaboration. He is currently the Head of Dermatology at Fundación Universitaria de Ciencias de la Salud in Bogota, Colombia and is a Dermatologist at Debra Colombia, dividing his time among three major teaching hospitals and private practice.

Natural Cannabinoid Active Pharmaceutical Ingredients: From Seed to API

Samantha Watt, MSc, Avicanna Inc.

Samantha’s experience investigating human physiology and cellular biology has allowed her to develop sophisticated laboratory and project management skills that contribute to Avicanna’s competitive edge in the department of Research and Development. More specifically, Samantha has been published on several different occasions and has also lead various conferences and presentations related to plant gene manipulation and cloning. Samantha received a Master of Science degree in from the University of Guelph.

Abstract: The cannabis industry has become inundated with a focus on mass cultivation. However, the sophistication of cannabis research has generated a flourishing shift in focus toward products comprised of whole-plant extracts and isolated phytochemicals. Notably, isolated cannabinoids have become a focal point within the market and have become recognized as Active Pharmaceutical Ingredients (APIs). This new wave of technological advancements has built a platform that is centred around the extraction of cannabinoid compounds to capture the unique pharmaceutical applications. This presentation will outline the multi-stage process of harvesting cannabis and will address the hurdles that surround the process of extraction and purification from the delicate trichomes of the plant into desirable APIs.

Dr. David Kideckel, PhD, AltaCorp Capital Inc.

Prior to joining AltaCorp Capital, Dr. Kideckel was at another leading independent investment dealer, in his role as Director of Healthcare & Biotechnology, Institutional Equity Research. Dr. Kideckel is a seasoned industry executive, having spent over 10 years in international pharmaceutical, biotechnology, and medical device companies where he held executive roles in sales, marketing, medical affairs and international business development. Dr. Kideckel holds a PhD and MBA from the University of Toronto’s Institute of Medical Science and Rotman School of Management, respectively. He is a university Gold Medalist and a recipient of the Canadian Institutes of Health Research Science to Business Award.

In addition, Javier serves as the Managing Director of Benzinga's Cannabis division, hosts and produces multimedia shows, sits on advisory boards at cannabis companies in emerging markets, has recorded songs that were featured on Billboard charting albums with big names like Wu Tang Clan's RZA and Twista, and publishes his photography very often.

Dr. Ignacio Peralta, PhD, University of Buenos Aires

Dr. Ignacio Peralta currently works at the Institute of Chemistry and Drug Metabolism (IQUIMEFA), National Scientific and Technical Research Council. Ignacio does research in Ethnobotany, Phytochemistry and Pharmacology and teaches Pharmacognosy and Phytotherapy at the School of Pharmacy and Biochemistry of University of Buenos Aires. Their most recent publication is ' Food Preservation by Larrea divaricata extract: Participation of Polyphenols’.

Alan Ridgway, PhD, Sprott Capital Partners

Alan Ridgeway has worked as a publishing research analyst for more than 10 years. Prior to joining Sprott Capital Partners he was a top ranked analyst covering the Canadian healthcare sector at Scotiabank. Prior to working in the capital markets, Mr. Ridgeway held a postdoctoral fellowship at Harvard Medical School where he performed cancer research. Mr. Ridgeway holds a PhD in Biochemistry from Western University, an MBA from Queen’s University, and is a CFA® Charterholder.

Dr. Rahul Sarugaser, PhD, Paradigm Capital Inc.

Rahul is an equities research analyst covering the biotechnology, healthcare, and cannabis sectors at Paradigm Capital. Rahul holds a PhD and MASc in biomedical engineering from the University of Toronto, and an MBA from the University of Oxford. Prior to Paradigm, his roles included Director of Business Development at the Centre for Commercialization of Regenerative Medicine, Investment Manager with the Toronto-based MaRS Investment Accelerator Fund, and Strategic Marketing Analyst with GE Healthcare’s headquarters in the U.K.

Healthcare Practitioner Perspective

Alex Chan, R.Ph., B.S.Phm., M.B.A., PharmAct Health Solutions

Alex is a licensed pharmacist and a graduate of the Faculty of Pharmacy, University of Toronto. He has worked for over 30 years in practically all aspects of pharmacy field —hospital pharmacist, community pharmacist manager, pharmacist owner, teaching assistant, PEBC examiner and admission interviewer (MMI) at the Faculty of Pharmacy, U of T. Alex has provided input to the Ontario Ministry of Health on pharmacy related issues. His academic achievements include MBA from the Ivey School of Business, University of Western Ontario.

Combined experience as a pharmaceutical sales representative and 10 years in Marketing has provided unique insights and expertise in the therapeutic areas of OTC, ADHD, OAB, pain management and opioids. As a Marketing Director at Purdue Pharma, Alex launched seven products and designed provincial formularies reimbursement agreements with successful listings, among other accomplishments. Alex managed a portfolio of opioid pain products with sales of $300 million. Alex is the owner of Solara Pharmacy with two locations that serve Etobicoke and Thornhill. In addition, he is a managing partner of Enhanced Care Medical Services, a preferred provider of medical clinic and physician services to McKesson Canada.

Abstract: In 2001, the federal government passed the Marihuana Medical Access Regulations allowing people who have obtained a medical authorization to access dried marijuana. Since this act was passed, healthcare practitioners are required to be more cautious and informed in order to maintain high safety and health standards for their patients. We will explore the HCPs’ perspective and its impact on patient care, including how evidence-based medicine, formulation and dose standards, compliance and drug interactions have affected patient care. We will discuss the future of the healthcare practitioner in medical cannabis, and how to work collaboratively with all stakeholders involved with patient care.

Dr. Carlos Maldonado, MD, Universidad Nacional

Dr. Carlos Enrique Maldonado Muete is a physician, pharmacologist and professor of pharmacology who contributes his experience in biotechnology, pharmacovigilance, clinical studies and knowledge of the medical community and regulatory authorities, as a local and international lecturer. Among other roles, he has participated in medical and regulatory issues related to the approval and commercialization of several new medicines. Dr. Muete has achieved results through his role as a former Medical Director of international pharmaceutical companies and as an external advisor.

Dr. Nimish Purohit, MBBS, DPM, MRCPsych, FRANZCP, FRCPC, Entourage Clinic

Dr. Purohit is the former Chief of Psychiatry at Joseph Brant Memorial Hospital (Burlington, Ontario) and an Assistant Clinical Professor (Adjunct) at McMaster Unversity. He practices as a consultant psychiatrist in his private practice and the Ontario Tele-Health Network. Dr. Purohit is a lead consultant in three methadone clinics in the Hamilton Region and the Princi- pal and Chief Consultant at a medical clinic specializing in the use and research of medical cannabis for a range of illnesses.

Dr. Carlo De Angelis, PharmD, Sunnybrook Health Sciences Centre

Carlo earned his Bachelor of Science in Pharmacy from the University of Toronto in 1981 and completed a Hospital Pharmacy Residency at Sunnybrook Health Sciences Centre in 1982. He graduated with a Doctor of Pharmacy from the State University of New York at Buffalo in 1984. From 1985 to 2011, Carlo was the Clinical Pharmacy Coordinator for Oncology at Sunnybrook Odette Cancer Centre and is currently the Oncology Pharmacy Clinician Scientist at the Odette.

He is an Assistant Professor at the Leslie Dan Faculty of Pharmacy, University of Toronto where he co-coordinates the third year Oncology Therapeutics Course. Carlo has given numerous presentations at local, national and international meetings on various oncology related topics.

Clinical Development Plan for Cannabinoids

Dr. Humberto Reynales, MD, PhD, Centro De Atención E Investigación Médica

Dr. Reynales is an MD in Internal Medicine. He holds a MSc in Epidemiology an MBA from Duke University and a PhD in Preventive Medicine from the University of Sao Paulo, Brazil and has completed a Global Clinical Scholars Research Training Program at Harvard Medical School. He has more than 15 years of experience in the pharmaceutical industry with Merck & Co in the area of Clinical Research. Since 2009, he is the founder and Executive Director of CAIMED, a private clinical research organization with operations in eleven sites and four countries in Latin America, and a leader in clinical trials implementation as well as design and conduct of clinical studies in several therapeutic areas.

Abstract: Cannabinoids have been used for many years for treatment on a diversity of symptoms and medical conditions. Due to their psychotropic effect and its legal status most of the research is anecdotic. However many publications in several therapeutic areas and with different level of evidence and quality have been released for years in pre-clinical and clinical settings. We present a review of the research experience with cannabinoids and its potential for future research in different therapeutic areas and the need for well designed valid and powered studies in order to create strong evidence.

Canadian Regulatory Landscape

Dr. Edith Gorecki, MD dicentra Cannabis Consulting

Dr. Gorecki joins dicentra with over 8 years of clinical medicine experience in various therapeutic areas and patient care settings. After completing her family medical internship in the United States, she pursued her passion of helping others by participating in a Medical Mission in the Caribbean, followed by Oncology Research at the Geisel School of Medicine at Dartmouth in New Hampshire.Since 2015, Edith has been working with various Clinical Research Organizations in the Pharmaceutical and Nutraceutical industries. She has experience with organizing, managing and executing clinical trials (phases I-III) under ICH GCP guidelines in the US and Canada.

Abstract: With the discovery of the endocannabinoid system, isolated cannabinoids have been investigated to define therapeutic applications by conducting pre-clinical and clinical trials. With the federal government acknowledging the medical potential for cannabinoids, regulatory pathways have been developed for clinical trial development to ensure the safety and efficacy for the general public. Navigating through these pathways set forth by Health Canada may be daunting and covered with red tape, however with the proper guidance, applications for clinical trial approval will ensure Good Clinical Practice (GCP) standards are followed and that the use of the cannabinoids being studied in patients are appropriate.

Section 2: Regulatory Affairs and the Emerging Industry

Moderator: Dr. Hance Clarke, MD, PhD, University Health Network

Hance Clarke is a staff anesthesiologist and the Director of Pain Services and the Pain Research Unit at the Toronto General Hospital. Dr. Clarke is currently the knowledge Translation Chair For the University of Toronto Centre For the Study of Pain and in 2016, Dr. Clarke was awarded an early Career Award from the Canadian Pain Society. He has been recognized internationally for his research productivity and improvements to patient care such as the development of the Transitional Pain Program.

Dr. Clarke has also played a leading role in educating the Canadian public about pain control, risk factors for chronic opioid use, alternatives to opioids as a pioneering strategy at TGH, misconceptions about opioid use, and the need for further studies on understanding the beneficial and adverse effects of cannabis. He is a strong public champion of evidence-based solutions for the opioid crisis and a national pain and addictions strategy.

Toxicology and Pharmacology of Cannabinoids

Dr. Ruth Ross, PhD, University of Toronto

Ruth Ross is engaged in research into the molecular pharmacology of the cannabinoids and related lipid signalling systems. Her research is directed both toward gaining insight into the deleterious effects of cannabis smoking, the potential for cannabis a medicine and the development of small molecules targeting G protein coupled receptors. Together with medicinal chemists she is engaged in the development of novel small molecule therapeutics for major diseases including chronic pain, addiction, cancer and diabetes.

Abstract: The ‘endocannabinoids’ arachidonoylethanolamide (anandamide) and 2-arachidonoyl glycerol (2-AG) are synthesised on demand and are rapidly inactivated by enzymes. There is ample evidence that the levels of endocannabinoids are increased in both physiological and pathophysiological situations, in which an autoprotective action of the endocannabinoids has been also implicated. Mammalian tissues express at least two types of cannabinoid receptor, CB 1 and CB 2 , both G protein coupled receptors (GPCR). Endocannabinoids interact with cannabinoid receptors and levels are elevated in response to certain triggers. For example, they are increased in response to nerve injury – reducing pain and inflammation; they are increased in response to stress to elevate mood. As such, the endocannabinoid system is a promising target for management of certain conditions including, for example, pain and inflammation. The primary constituents of cannabis (THC and CBD) interact with the endocannabinoid system in various ways; leading to potential therapeutic effects, but which may be accompanied by side- effects. The goal of current research is to assess the safety and efficacy of THC and CBD in a range ofillnesses; identifying the molecular and cellular mechanisms of their action.

Dr. Lakshmi Kotra, B.Pharm.(Hons), PhD, University of Toronto

Dr. Kotra is an academic entrepreneur with expertise in drug discovery and development. Kotra group specializes in the areas of medicinal chemistry, preclinical and clinical development of small molecule and natural product-based drugs. Dr. Kotra authored/co-authored over 120 peer-reviewed articles and book chapters, and delivered over 110 scientific and plenary talks globally. Kotra research group has contributed to a number of research programs in the areas of infectious, metabolic and neurodegenerative diseases. Dr. Kotra is a recipient of several awards including the Premier’s Research Excellence Award from the Province of Ontario (Canada), Rx&D Health Research Foundation Research Career award, GlaxoSmithKline/Canadian Society for Pharmaceutical Sciences Young Investigator Award. Dr. Kotra leads an international consortium with India for the development of novel chemical classes of drugs targeting malaria—a consortium of public and private organizations in Canada and India. Dr. Kotra is a co-founder of WinSanTor Inc., San Diego, California, USA (drugs targeting diabetic neuropathy, 2012-present), CIDAVA Innovations—an India-Canada joint venture (antimalarials, 2013-17), CannScience Innovations, Inc., Toronto, Canada (now Scientus Pharma, Inc.; novel cannabinoid products for medical uses, 2014-17). He currently serves on the Board of Directors of WinSanTor Biosciences (San Diego, CA), Scientific Advisory Boards of Scientus Pharma Inc. (Toronto) where he maintains Chief Scientific Officer/consultant role, Montdorex Inc. (Montreal, Canada), and College of Reviewers at the Canadian Institutes of Health Research.

Dr. Janeth Mora, PhD, Avicanna Inc.

Dr. Mora is an executive within the pharmaceutical industry, with broad and qualified experience in regulatory affairs and marketing across emerging markets. Dr. Mora began her career with the Colombian Regulatory Agency, INVIMA, and then continued in the pharmaceutical industry with Merck & co. She later joined Pfizer Inc. in 1997 where she held different positions of increasing responsibility in regulatory affairs, and then subsequently in marketing for specialty/orphan products. Dr. Mora currently acts as a Strategy and Business Development Advisor for companies in LATAM interested in developing businesses in the region. Janeth also holds degrees in Management, Marketing and Negotiation.

Dr. Andres Zuluaga, PhD, University of Antioquia

Dr. Zuluaga is a full professor and senior researcher at Department of Pharmacology and Toxicology and he has been dedicated to research on aspects related to pharmacology, pharmacokinetics and pharmacodynamics, pharmacometrics, immunopharmacology, rational use of drugs, substance abuse and misuse, development of animal models of Therapeutic efficacy, chronic osteomyelitis, study of generics and biosimilars, dose optimization and software development.

Section 1: Cannabinoids and Formulations

Moderator: Dr. Chandra Panchal, PhD, Axcelon Biopolymers

Dr. Panchal has been the Chief Executive Officer of Axcelon Biopolymers since 2008, has authored over seventy scientific papers, holds several patents in oncology, diagnostics, biopolymers and microbiology, and is an Adjunct Professor in Chemical and Biochemical Engineering at the University of Western Ontario. Dr. Panchal currently sits on the board of directors of both an oncology company known as Medicenna Therapeutics (MDNA), and Canadian Oil Recovery and Remediation Inc. (CVR) as well as Pure Global Cannabis Inc. (PURE). Dr. Panchal holds a Master of Science degree in Molecular Biology and a Ph.D. in Biochemical Engineering from the University of Western Ontario.

An Introduction to Cannabinoid Formulation Development

Dr. Frantz Le Dévédec, PhD, Avicanna Inc.

Frantz has over 15 years of experience in academic and industrial R&D projects, including material sciences and drug delivery formulations. He is author of over a dozen research papers and patents. His background is in biochemistry, with a PhD in applied polymer chemistry, and expertise in analytical and pharmaceutical sciences.

Abstract: Similar to more than 40% of active pharmaceutical ingredients (APIs), cannabinoids have limited aqueous solubility, which creates challenges in formulation development and administration (e.g. oral, injectable, dermal routes). In order to improve the bioavailability and efficacy of these APIs for use in specific indications there is a need for well-designed drug formulations. The formulations must improve the solubility and stability of the API while resulting in sufficient bioavailability to yield the desired therapeutic effect and assure good safety and toxicity profiles. Attention must also be given to the scalability of the formulation to ensure translation from pre-clinical lab bench to industrial production. This seminar will provide an overview of the many considerations behind rational cannabinoid formulation design and strategies to ensure successful tech transfer to industrial scale development.

Moderator: Dr. Chandra Panchal, PhD, Axcelon Biopolymers

Dr. Panchal has been the Chief Executive Officer of Axcelon Biopolymers since 2008, has authored over seventy scientific papers, holds several patents in oncology, diagnostics, biopolymers and microbiology, and is an Adjunct Professor in Chemical and Biochemical Engineering at the University of Western Ontario. Dr. Panchal currently sits on the board of directors of both an oncology company known as Medicenna Therapeutics (MDNA), and Canadian Oil Recovery and Remediation Inc. (CVR) as well as Pure Global Cannabis Inc. (PURE). Dr. Panchal holds a Master of Science degree in Molecular Biology and a Ph.D. in Biochemical Engineering from the University of Western Ontario.

Welcome and Key Note Remarks

Dr. Christine Allen, Professor, Leslie Dan Faculty of Pharmacy, University of Toronto and Chief Scientific Officer, Avicanna Inc.

Christine Allen is a Professor in the Leslie Dan Faculty of Pharmacy at the University of Toronto and Chief Scientific Officer at Avicanna Inc. At the University of Toronto, Dr. Allen’s research is focused on the design and development of new materials and technologies for drug delivery with over 130 peer-reviewed publications in this area. She has received career awards from CIHR-Rx&D, CSPS and AFPC. Christine completed her doctoral research in the Department of Chemistry at McGill University and post-doctoral research in the Department of Advanced Therapeutics at the B.C. Cancer Agency. She joined University of Toronto from Celator Pharmaceuticals Inc. Christine is President Elect of the Canadian Society for Pharmaceutical Sciences (CSPS) and a member of the Governing Council for the Natural Sciences and Engineering Research Council of Canada.

Abstract: This is an exciting time for the medical cannabis industry with new medical cannabis products in late stage pre-clinical and clinical development, clinical product approvals and industry deals totaling billions of dollars. However, the two most studied cannabinoids, cannabidiol and tetrahydrocannabinol, are beginning to be considered a cure-all for near to every minor ailment and chronic condition. Is this cause for concern? Another emerging critical question is whether or not scientific data and medical evidence support the current level of interest and investment in this area. This presentation addresses these questions and draws attention to the importance of recognizing that “legal and natural” are not equivalent to “safe and effective”. An overview of the historical use of medical cannabis with an emphasis on the latest groundbreaking developments will be provided. Medical cannabis formulations that are currently on the market will be reviewed with critical analysis of available clinical efficacy and safety data. Moreover, recommendations for pre-clinical and clinical studies will be provided with a goal towards the development of products that are safe and effective, and result in meaningful improvements in patient outcomes.